clinical trial · NCT07790380
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
Jiangsu HengRui Medicine Co., Ltd.·phase3·not yet recruiting·n = 480
Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based ChemotherapyFH-006Paclitaxel, Docetaxel, Irinotecan
brief summary
The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.
started
Oct 10, 2026
primary completion
Jun 30, 2029
completion
Jun 30, 2029
last updated
Aug 27, 2026
official title
A Randomized, Open-label, Multicenter, Phase III Study of FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol